Dr. Carrasco has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Abbott.
Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference
Article first published online: 27 MAR 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 4, pages 546–553, April 2012
How to Cite
Huber, A. M., Robinson, A. B., Reed, A. M., Abramson, L., Bout-Tabaku, S., Carrasco, R., Curran, M., Feldman, B. M., Gewanter, H., Griffin, T., Haines, K., Hoeltzel, M. F., Isgro, J., Kahn, P., Lang, B., Lawler, P., Shaham, B., Schmeling, H., Scuccimarri, R., Shishov, M., Stringer, E., Wohrley, J., Ilowite, N. T., Wallace, C. and Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance (2012), Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res, 64: 546–553. doi: 10.1002/acr.20695
- Issue published online: 27 MAR 2012
- Article first published online: 27 MAR 2012
- Accepted manuscript online: 10 NOV 2011 11:14AM EST
- Manuscript Accepted: 24 OCT 2011
- Manuscript Received: 10 JUL 2011
- NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. Grant Numbers: RC1AR058605-01, R13-AR053058-04
- Childhood Arthritis and Rheumatology Research Alliance
- Arthritis Foundation
- Wasie Foundation
- Friends of the Childhood Arthritis and Rheumatology Research Alliance
To use consensus methods and the considerable expertise contained within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) organization to extend the 3 previously developed treatment plans for moderate juvenile dermatomyositis (DM) to span the full course of treatment.
A consensus meeting was held in Chicago on April 23–24, 2010, involving 30 pediatric rheumatologists and 4 lay participants. Nominal group technique was used to achieve consensus on treatment plans that represented typical management of moderate juvenile DM. A preconference survey of CARRA, completed by 151 (56%) of 272 members, was used to provide additional guidance to the discussion.
Consensus was reached on timing and rate of steroid tapering, duration of steroid therapy, and actions to be taken if patients were unchanged, worsening, or experiencing medication side effects or disease complications. Of particular importance, a single consensus steroid taper was developed.
We were able to develop consensus treatment plans that describe therapy for moderate juvenile DM throughout the treatment course. These treatment plans can now be used clinically, and data collected prospectively regarding treatment effectiveness and toxicity. This will allow comparison of these treatment plans and facilitate the development of evidence-based treatment recommendations for moderate juvenile DM.